EICHORCondition: Melanoma of Unknown Primary · Metastatic Malignant Neoplasm in Lymph Node · Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 · Sponsor: ECOG-ACRIN Cancer Research Group
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib may provide more information on melanoma over time.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Los Angeles County-USC Medical Center | Los Angeles, California, United States | — |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan, United States | — |
| Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters, Missouri, United States | — |
| Siteman Cancer Center at West County Hospital | Creve Coeur, Missouri, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
| Siteman Cancer Center-South County | St Louis, Missouri, United States | — |
| Siteman Cancer Center at Christian Hospital | St Louis, Missouri, United States | — |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | — |
| University of Wisconsin Carbone Cancer Center | Madison, Wisconsin, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04221438